This content is from: Premium
Hedge-Fund-Backed Acelyrin Makes a Strong IPO Debut
In a brutal IPO environment, the biopharma company soared 30 percent in its first day of trading.
Acelyrin, a late-stage clinical biopharma company focused on the development and delivery of transformative medicines in immunology, hit the ground running in its first day of trading on Friday, posting roughly a 30 percent gain over its IPO price. The stock then tacked on another
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.